Literature DB >> 22270980

Partial pathologic response and nodal status as most significant prognostic factors for advanced rectal cancer treated with preoperative chemoradiotherapy.

Marianne Huebner1, Bruce G Wolff, Thomas C Smyrk, Jeremiah Aakre, David W Larson.   

Abstract

BACKGROUND: This study evaluated the impact of tumor regression grading (TRG) and other pathologic variates in a cohort of rectal carcinoma patients treated with neoadjuvant chemoradiotherapy (CRT). The value of a grading less than pCR for predicting survival is unknown. Tumor budding has not been systematically studied in rectal cancer after neoadjuvant therapy.
METHODS: Pathologic risk factors for survival were evaluated on surgical specimens of 237 patients with stages I, II, and III rectal cancer treated between 1996 and 2006. All patients underwent preoperative CRT followed by surgical resection 6-8 weeks later. TRG, tumor grade, budding, venous invasion, radial margin, and nodal status were evaluated. The prognostic value of TRG categories was calculated with Cox regression models and validated with resampling methods.
RESULTS: TRG of <25% occurred in 61 (25.7%) and a complete response in 39 (16.4%) of the resected specimens. TRG of <25% was shown to be a statistically significant predictor for cancer-specific survival (CSS) and recurrence-free survival (RFS) compared to TRG ≥25% (P = 0.013). Tumor budding was present in 24 (10.1%) of the patients and was negatively associated with CSS (P = 0.013). Lymph node involvement was observed in 83 (35.0%) patients. TRG and nodal status (P < 0.001) were the most significant predictors associated with outcome.
CONCLUSION: Partial pathologic response ≥25% was a superior predictor compared to pCR for improved survival after preoperative CRT. CSS and RFS were adversely affected by the presence of lymph node metastases.

Entities:  

Mesh:

Year:  2012        PMID: 22270980     DOI: 10.1007/s00268-011-1409-8

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  24 in total

1.  Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients.

Authors:  Carlo Capirci; Vincenzo Valentini; Luca Cionini; Antonino De Paoli; Claus Rodel; Robert Glynne-Jones; Claudio Coco; Mario Romano; Giovanna Mantello; Silvia Palazzi; Falchetti Osti Mattia; Maria Luisa Friso; Domenico Genovesi; Cristiana Vidali; Maria Antonietta Gambacorta; Alberto Buffoli; Marco Lupattelli; Maria Silvia Favretto; Giuseppe La Torre
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-11       Impact factor: 7.038

2.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

Authors:  Claus Rödel; Peter Martus; Thomas Papadoupolos; Laszlo Füzesi; Martin Klimpfinger; Rainer Fietkau; Torsten Liersch; Werner Hohenberger; Rudolf Raab; Rolf Sauer; Christian Wittekind
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

3.  Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer.

Authors:  H Ueno; J Murphy; J R Jass; H Mochizuki; I C Talbot
Journal:  Histopathology       Date:  2002-02       Impact factor: 5.087

4.  Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.

Authors:  Mark S Roh; Linda H Colangelo; Michael J O'Connell; Greg Yothers; Melvin Deutsch; Carmen J Allegra; Morton S Kahlenberg; Luis Baez-Diaz; Carol S Ursiny; Nicholas J Petrelli; Norman Wolmark
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

5.  Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma.

Authors:  Takashi Okuyama; Masatoshi Oya; Hiroshi Ishikawa
Journal:  J Surg Oncol       Date:  2003-05       Impact factor: 3.454

6.  Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer.

Authors:  Matthew F Kalady; Luiz Felipe de Campos-Lobato; Luca Stocchi; Daniel P Geisler; David Dietz; Ian C Lavery; Victor W Fazio
Journal:  Ann Surg       Date:  2009-10       Impact factor: 12.969

7.  Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer.

Authors:  J Suárez; R Vera; E Balén; M Gómez; F Arias; J M Lera; J Herrera; C Zazpe
Journal:  Colorectal Dis       Date:  2007-12-07       Impact factor: 3.788

8.  Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation.

Authors:  Kerrington D Smith; Dongfeng Tan; Prajnan Das; George J Chang; Kiran Kattepogu; Barry W Feig; John M Skibber; Miguel A Rodriguez-Bigas
Journal:  Ann Surg       Date:  2010-02       Impact factor: 12.969

9.  Prognostic value of tumor "budding" in patients with colorectal cancer.

Authors:  K Hase; C Shatney; D Johnson; M Trollope; M Vierra
Journal:  Dis Colon Rectum       Date:  1993-07       Impact factor: 4.585

10.  Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer.

Authors:  Lai Mun Wang; David Kevans; Hugh Mulcahy; Jacintha O'Sullivan; David Fennelly; John Hyland; Diarmuid O'Donoghue; Kieran Sheahan
Journal:  Am J Surg Pathol       Date:  2009-01       Impact factor: 6.394

View more
  27 in total

1.  Factors influencing response to neoadjuvant chemoradiation and outcomes in rectal cancer patients: tertiary Indian cancer hospital experience.

Authors:  Reena Engineer; Trinanjan Basu; Supriya Chopra; Supreeta Arya; Prachi Patil; Shaesta Mehta; Mukta Ramadwar; Kedar Deodhar; Shyam Kishore Shrivastava
Journal:  J Gastrointest Oncol       Date:  2015-04

2.  Changing operative strategy from abdominoperineal resection to sphincter preservation in T3 low rectal cancer after downstaging by neoadjuvant chemoradiation: a preliminary report.

Authors:  Khaled M Madbouly; Ahmed M Hussein
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

3.  Reduction in the size of enlarged pelvic lymph nodes after chemoradiation therapy is associated with fewer lymph node metastases in locally advanced rectal carcinoma.

Authors:  Mitsuaki Morimoto; Yasuyuki Miyakura; Alan T Lefor; Kazuya Takahashi; Hisanaga Horie; Koji Koinuma; Hiroyuki Tanaka; Homare Ito; Tetsuichiro Shimizu; Yoshihiko Kono; Naohiro Sata; Noriyoshi Fukushima; Takashi Sakatani; Yoshikazu Yasuda
Journal:  Surg Today       Date:  2014-08-15       Impact factor: 2.549

Review 4.  Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy.

Authors:  Rupert Langer; Karen Becker
Journal:  Virchows Arch       Date:  2017-09-16       Impact factor: 4.064

5.  Impact of RAS/BRAF mutation status in locally advanced rectal cancer treated with preoperative chemotherapy.

Authors:  Taihei Oshiro; Keisuke Uehara; Toshisada Aiba; Toshiki Mukai; Tomoki Ebata; Masato Nagino
Journal:  Int J Clin Oncol       Date:  2018-02-24       Impact factor: 3.402

Review 6.  Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.

Authors:  Alessandro Lugli; Richard Kirsch; Yoichi Ajioka; Fred Bosman; Gieri Cathomas; Heather Dawson; Hala El Zimaity; Jean-François Fléjou; Tine Plato Hansen; Arndt Hartmann; Sanjay Kakar; Cord Langner; Iris Nagtegaal; Giacomo Puppa; Robert Riddell; Ari Ristimäki; Kieran Sheahan; Thomas Smyrk; Kenichi Sugihara; Benoît Terris; Hideki Ueno; Michael Vieth; Inti Zlobec; Phil Quirke
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

7.  Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial.

Authors:  Erhan Akgun; Cemil Caliskan; Osman Bozbiyik; Tayfun Yoldas; Basak Doganavsargil; Serdar Ozkok; Timur Kose; Bulent Karabulut; Nevra Elmas; Omer Ozutemiz
Journal:  BJS Open       Date:  2022-09-02

8.  Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy.

Authors:  Atin Agarwal; George J Chang; Chung-Yuan Hu; Melissa Taggart; Asif Rashid; In J Park; Y Nancy You; Prajnan Das; Sunil Krishnan; Christopher H Crane; Miguel Rodriguez-Bigas; John Skibber; Lee Ellis; Cathy Eng; Scott Kopetz; Dipen M Maru
Journal:  Cancer       Date:  2013-10-01       Impact factor: 6.860

9.  A Phase II Study of Additional Four-Week Chemotherapy With Capecitabine During the Resting Periods After Six-Week Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.

Authors:  Kyung Ha Lee; Min Sang Song; Jun Boem Park; Jin Soo Kim; Dae Young Kang; Ji Yeon Kim
Journal:  Ann Coloproctol       Date:  2013-10-31

Review 10.  Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials.

Authors:  Thomas J George; Carmen J Allegra; Greg Yothers
Journal:  Curr Colorectal Cancer Rep       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.